PinnyPeptide

Bronchogen vs Crystagen

Side-by-side comparison: effects, dosing ranges, side effects, regulatory status, and reconstitution.

Peptide A

Bronchogen

Bioregulators

Khavinson short peptide bioregulator targeting bronchial epithelium and lung tissue.

Peptide B

Crystagen

Bioregulators

Khavinson short peptide bioregulator targeting thymus / immune cells.

Typical vial

20 mg

Typical dose

1,000-5,000 mcg

Half-life

Short (minutes); biological effect persists longer via gene-expression modulation

FDA status

Not FDA approved.

Typical vial

20 mg

Typical dose

1,000-5,000 mcg

Half-life

Short (minutes); biological effect persists via gene-expression modulation

FDA status

Not FDA approved.

Bronchogen effects

  • Reported restoration of bronchial epithelial function
  • Improvement in pulmonary function tests (Russian observational data)
  • Reduction in COPD/bronchitis exacerbation frequency
  • Improved dyspnea and exercise tolerance
  • Anti-inflammatory effects in bronchial tissue

Crystagen effects

  • Reported improvement in T-cell numbers and function
  • Restoration of age-related immune decline (Russian observational)
  • Support of thymic function in elderly patients
  • Anti-inflammatory effects
  • Recovery support after severe illness

Bronchogen side effects

  • Generally well-tolerated in Russian clinical use
  • Mild injection-site reactions
  • Occasional allergic reactions (rare)
  • Limited Western safety validation

Crystagen side effects

  • Generally well-tolerated in Russian clinical use
  • Mild injection-site reactions
  • Limited Western safety validation
  • Theoretical: caution in active autoimmune disease (immune modulation)

Bronchogen dosing ranges

Bronchial function support

1-5 mg · Once daily (SubQ) or sublingual · 10-20 day cycles, repeated 2-3 times per year

Crystagen dosing ranges

Immune support

1-5 mg · Once daily (SubQ) or sublingual · 10-20 day cycles, repeated 2-3 times per year

Full Bronchogen guide → Full Crystagen guide →

Bronchogen vs Crystagen — common questions

What is the difference between Bronchogen and Crystagen?

Bronchogen: Khavinson short peptide bioregulator targeting bronchial epithelium and lung tissue. Typical dose 1,000-5,000 mcg. Crystagen: Khavinson short peptide bioregulator targeting thymus / immune cells. Typical dose 1,000-5,000 mcg. Both fall under the Bioregulators category.

Can you stack Bronchogen and Crystagen?

Stacking Bronchogen with Crystagen is a protocol-design question best raised with a clinician — it depends on your goal, current bloodwork, and whether both peptides target overlapping mechanisms. Both peptides should be tracked independently with separate injection sites and timing. PinnyPeptide supports multi-peptide stacks with automatic injection site rotation.

Which is dosed more frequently, Bronchogen or Crystagen?

Bronchogen is typically dosed: Once daily (SubQ) or sublingual for Bronchial function support. Crystagen is typically dosed: Once daily (SubQ) or sublingual for Immune support.

Are Bronchogen and Crystagen FDA approved?

Bronchogen: Not FDA approved. Crystagen: Not FDA approved.

Related peptide comparisons

bronchogen vs cardiogenbronchogen vs cartalaxbronchogen vs cortagenbronchogen vs ovagenbronchogen vs pancragencardiogen vs crystagen

Tracking either of these?

Log doses, automate injection site rotation, and never lose track of where you last pinned. Free forever.

Get Started Free